

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)



(10) International Publication Number
WO 2022/140284 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 35/17 (2014.01)
C07K 14/725 (2006.01) A61P 35/00 (2006.01)
C12N 15/62 (2006.01)

(21) International Application Number:

PCT/US2021/064408

(22) International Filing Date:

20 December 2021 (20.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/129,340 22 December 2020 (22.12.2020) US

(71) Applicant: IMMUNITYBIO, INC. [US/US]; 9920 Jefferson Boulevard, Culver City, California 90232 (US).

(72) Inventors: BOISSEL, Laurent H.; 9920 Jefferson Boulevard, Culver City, California 90232 (US). SIMON, Barry J.; 9920 Jefferson Boulevard, Culver City, California 90232 (US). HU, Wenjie; 9920 Jefferson Boulevard, Culver City,

California 90232 (US). KLINGEMANN, Hans G.; 9920 Jefferson Boulevard, Culver City, California 90232 (US).

(74) Agent: FESSENMAIER, Martin et al.; Umberg Zipser LLP, 1920 Main Street, Suite 750, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: FC-RECEPTOR CAR CONSTRUCTS AND CELLS




FIG.1

(57) Abstract: Chimeric antigen receptors with an antibody-binding domain are presented that are preferably expressed from a recombinant cell in a therapeutic cell, and particularly in an NK-92 cell or derivative thereof. Notably, such modified cells have multiple modes of cytotoxicity, improved on-target cell killing, decreased off-target cell killing, show significant expression of the recombinant CAR, and/or increased CAR-mediated cytotoxicity.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with amended claims and statement (Art. 19(1))*
- *with sequence listing part of description (Rule 5.2(a))*